Targeting of HIV- and SIV-infected cells by CD4-chemokine receptor pseudotypes.
about
Virus-like particles as quantitative probes of membrane protein interactionsTargeted infection of HIV-1 Env expressing cells by HIV(CD4/CXCR4) vectors reveals a potential new rationale for HIV-1 mediated down-modulation of CD4Molecular engineering of viral gene delivery vehiclesN-linked glycosylation of CXCR4 masks coreceptor function for CCR5-dependent human immunodeficiency virus type 1 isolates.Retroviral vector targeting to human immunodeficiency virus type 1-infected cells by receptor pseudotypingSoluble receptor-induced retroviral infection of receptor-deficient cellsShift of clinical human immunodeficiency virus type 1 isolates from X4 to R5 and prevention of emergence of the syncytium-inducing phenotype by blockade of CXCR4Nef enhances human immunodeficiency virus type 1 infectivity resulting from intervirion fusion: evidence supporting a role for Nef at the virion envelope.Cell-free assay of G-protein-coupled receptors using fluorescence polarization.Detection of proton movement directly across viral membranes to identify novel influenza virus M2 inhibitors.TANK-binding kinase 1 attenuates PTAP-dependent retroviral budding through targeting endosomal sorting complex required for transport-I.A biosensor assay for studying ligand-membrane receptor interactions: binding of antibodies and HIV-1 Env to chemokine receptorsEngineered lentiviral vectors pseudotyped with a CD4 receptor and a fusogenic protein can target cells expressing HIV-1 envelope proteins.Multiple roles for chemokines in the pathogenesis of SIV infectionSelective killing of HIV-1-positive macrophages and T cells by the Rev-dependent lentivirus carrying anthrolysin O from Bacillus anthracis.Nef can enhance the infectivity of receptor-pseudotyped human immunodeficiency virus type 1 particles.Lentiviral vectors for immune cells targeting.CD4-Chemokine receptor hybrids in human immunodeficiency virus type 1 infection.CXCR4 sequences involved in coreceptor determination of human immunodeficiency virus type-1 tropism. Unmasking of activity with M-tropic Env glycoproteins.Incorporation of wild-type and C-terminally truncated human epidermal growth factor receptor into human immunodeficiency virus-like particles: insight into the processes governing glycoprotein incorporation into retroviral particles.Role of Vif in stability of the human immunodeficiency virus type 1 coreProperties of wild-type, C-terminally truncated, and chimeric maedi-visna virus glycoprotein and putative pseudotyping of retroviral vector particles.Lipid rafts and pseudotyping.Inhibition of HIV-1 infection and replication by enhancing viral incorporation of innate anti-HIV-1 protein A3G: a non-pathogenic Nef mutant-based anti-HIV strategy.Chemokines and HIV-1 second receptors: the therapeutic connection.Anti-human immunodeficiency virus drug combination strategies.Organ distribution of gene expression after intravenous infusion of targeted and untargeted lentiviral vectors.Isolation of state-dependent monoclonal antibodies against the 12-transmembrane domain glucose transporter 4 using virus-like particles.
P2860
Q24657310-1245B387-01C1-45DB-8FB2-C3891AE90F31Q25257643-B1AD1580-A087-40C8-BD38-C99F58D8193AQ33353795-2B906558-4131-4E3C-BEF7-2EB502267FA5Q33804016-DE48A5BB-55D0-43CB-8B41-65AC47F10D87Q33804059-47BEAD5D-4337-4D2B-A0CF-3498A1088891Q33807796-393969BD-B91C-4EF6-821F-39A97EF8E3A5Q33815285-D64AF1E1-D273-4E32-A706-7238477DB937Q33842252-09464F32-1CA8-4063-BAC0-3E8415E5AF5DQ34787797-CDA9ADC5-190E-4F05-BC49-6C3E14EB6D4CQ34864675-B0044148-E102-451A-946F-FEDB4C19CC8FQ35022871-0EB1AA97-0549-416C-AB37-3AA4BF0B4F81Q35263959-79E3AC09-EB45-492A-83CF-2916C6E6DC7EQ36390352-1A5AD30C-9072-4EF9-8AC1-BA8C087779EBQ36634172-BDCBB05D-540D-4D93-807A-4CF658719A65Q36667599-959ED947-C73D-4546-BFE4-62220A6F8456Q36949578-FF9F889E-304C-42E5-92CC-A1DD403C747AQ37677792-D4BD4D5C-F322-4ED2-A5F7-74BD57FDDF82Q39550956-1C6A37E6-811E-4AB0-9F7B-3C515133E2B0Q39577767-CA055A58-57C2-4A03-8219-06D84B233D97Q39596501-1EFD3CA4-C3B9-4EEC-9E3C-F8B6DCCD3ADEQ39597709-1A61EF1B-E916-4297-8D85-DF544BFC2547Q39601359-BD61E4EE-D280-4A34-9244-A96206046EFCQ39603900-4C9FB1E2-A399-45BE-A2BD-B7BF230E94B3Q41889687-CB9C604D-30D3-45E3-9032-13855BCB0BB8Q43938781-58B3CDEF-B2CB-4FA3-B704-6A517D5D27EDQ45752028-E824B104-94CE-46B7-90D9-CACC2B09C2A5Q45880348-5AB94859-1C59-4B47-A86E-7A5495D47727Q53819033-4856CCEB-FA33-4BF3-BF1B-D63A5213261C
P2860
Targeting of HIV- and SIV-infected cells by CD4-chemokine receptor pseudotypes.
description
1997 nî lūn-bûn
@nan
1997年の論文
@ja
1997年学术文章
@wuu
1997年学术文章
@zh-cn
1997年学术文章
@zh-hans
1997年学术文章
@zh-my
1997年学术文章
@zh-sg
1997年學術文章
@yue
1997年學術文章
@zh
1997年學術文章
@zh-hant
name
Targeting of HIV- and SIV-infected cells by CD4-chemokine receptor pseudotypes.
@en
type
label
Targeting of HIV- and SIV-infected cells by CD4-chemokine receptor pseudotypes.
@en
prefLabel
Targeting of HIV- and SIV-infected cells by CD4-chemokine receptor pseudotypes.
@en
P2093
P1433
P1476
Targeting of HIV- and SIV-infected cells by CD4-chemokine receptor pseudotypes.
@en
P2093
Haggarty B
O'Brien PJ
P304
P356
10.1126/SCIENCE.278.5342.1462
P407
P577
1997-11-01T00:00:00Z